← Russell 3000 cross-section

ARWR ARROWHEAD PHARMACEUTICALS, INC.

Trailing twelve months to 2026-06-30 · as filed 2026-08-04, not restated
Healthcare

Scale

Market cap
$12.5bn
Revenue TTM
$670m
Net income TTM
$-320m
Free cash flow
$-75m
Composite score
Sector rank
#618

Valuation

P / E
EV / EBITDA
EV / sales
16.4
FCF yield
-0.60%
Earnings yield vs 10-yr
-7.28pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-47.8%
EBITDA margin
-30.2%
ROE
-68.7%
ROIC
Revenue growth
16.9%

Insider activity, last 90 days

Net open-market
$-1.19m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Arrowhead is also eligible to receive development, regulatory, and sales milestone payments of up to $975 million. Additionally, the Company is eligible to receive up to $2.0 billion in potential milestone payments plus royalties on commercial sales. RESULTS OF OPERATIONS The following data summarizes the Company’s results of operations for the following periods indicated: Revenue Total revenue for the three and nine months ended June 30, 2026 increased by $47.5 million and decreased by $160.0 million, respectively, as compared to the same periods of 2025. …ARROWHEAD PHARMACEUTICALS, INC., 10-Q, period ended 2026-06-30, filed 2026-08-04

Read the full passage →